Eva Soler Espejo։ Atherogenic Index of Plasma and Residual Risk in Atrial Fibrillation
Eva Soler Espejo, Consultant Hematologist at Virgen de la Arrixaca University Clinical Hospital, shared a post on LinkedIn about a recent article she co-authored with her colleagues, adding:
”Anticoagulation in atrial fibrillation reduces risk — but does not eliminate it completely.
I am very pleased to share our latest publication in the Journal of the American Heart Association (JAHA).
In this prospective real-world study of anticoagulated patients with atrial fibrillation, we investigated whether the Atherogenic Index of Plasma (AIP) could help identify residual cardiovascular and thromboembolic risk.
Higher AIP levels were independently associated with worse clinical outcomes, particularly thromboembolic events and major adverse cardiovascular events (MACE), suggesting that this simple metabolic marker may provide incremental prognostic value beyond conventional risk assessment.
These findings underline the importance of better understanding residual risk in order to move towards more personalised and comprehensive management strategies in patients with AF.”
Title: Atherogenic Index of Plasma and Residual Risk in Anticoagulated Patients With Atrial Fibrillation: The Prospective Murcia Atrial Fibrillation Project III Cohort
Authors: Eva Soler‐Espejo, Yang Chen, José M. Rivera‐Caravaca, María P. Ramos‐Bratos, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip
Read the Full Article on Journal of the American Heart Association
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 27, 2026, 05:53Manuel Gutiérrez de Ravé: My Personal Takeaways from 39th International ISBT Annual Congress
-
Jun 27, 2026, 05:4710-Minute Paper-Strip Test Detects Factor VIII Inhibitors in Resource-Limited Settings – JTH
-
Jun 27, 2026, 05:23New episode – From Groundbreaking Therapies to the Ongoing Fight for Diagnosis – Global Hemophilia Report
-
Jun 27, 2026, 05:08Bethany Brown: Over 400 Ground EMS Agencies Now Carry Lifesaving Blood
-
Jun 27, 2026, 04:56Reza Shojaei: The Plasma Risk Governments Are Ignoring
-
Jun 27, 2026, 01:31Alessio De Rose: Addressing Micronutrient Deficiencies in the Era of GLP-1 Receptor Agonists
-
Jun 27, 2026, 01:21Michelle Sámano Sánchez: Exploring Vitamin C as an Adjunct Therapy for Anemia in Hemodialysis
-
Jun 27, 2026, 01:08Ana Raquel Gotine: The First Pragmatic Clinical Trial on MNPs and Childhood Anemia in Mozambique
-
Jun 27, 2026, 00:56Sherif Badawy: Reflecting on My Time with ASH CRTI